This article was originally published in The Gray Sheet
Executive SummaryAcquisition of nucleic acid testing technology developer Xtrana by in vitro diagnostic reagent maker Biopool International under a definitive stock-swap agreement announced May 4 is valued at about $9.5 mil. based on Biopool's May 4 closing price of $1.01 per share. Under the terms of the deal, all outstanding shares of Xtrana will be converted into approximately 9.4 mil. newly issued Biopool shares. As a result, current Xtrana and Biopool stockholders will hold about 50% of the combined company
You may also be interested in...
The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.
Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.